Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm)
| Autor: | John Kelly, Luke Tysall, Simon Dewar |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Microbiology (medical) Enterococcus faecium Microbial Sensitivity Tests biochemical phenomena metabolism and nutrition bacterial infections and mycoses Anti-Bacterial Agents Vancomycin-Resistant Enterococci Infectious Diseases Daptomycin Vancomycin Sepsis polycyclic compounds Humans Pharmacology (medical) Gram-Positive Bacterial Infections |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 77:1432-1435 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dkac042 |
| Popis: | Background There is in vitro and clinical evidence to suggest daptomycin has good activity against Enterococcus. In 2019, CLSI produced clinical breakpoints for Enterococcus spp. Objectives To describe the distribution of MICs of daptomycin for enterococcal bloodstream infection (EBSI) isolates in a large Scottish health board, the indications for local daptomycin susceptibility testing and daptomycin doses used in vancomycin-resistant Enterococcus faecium (VREfm) infection. Methods We investigated all EBSIs over a 21 month period and identified isolates tested against daptomycin. We recorded the distribution of MICs, as well as indications for daptomycin susceptibility testing and information on daptomycin dosing, where it was used. Results There were 293 blood culture isolates of Enterococcus spp., of which 37 had daptomycin susceptibility testing performed, from 31 individual patients. Of the 293 isolates, 103 were E. faecium, of which 63 were VREfm. Daptomycin testing was indicated by vancomycin resistance in 24/37 isolates. All E. faecium isolates tested were in the CLSI ‘susceptible dose-dependent (SDD)’ range of MICs. All other Enterococcus spp. tested were in the ‘susceptible’ range. Twelve patients received daptomycin, and dosing information was recovered for 10. Nine of these patients received 8–12 mg/kg/day dosing. There were no recorded adverse drug reactions. Ten of 12 patients were alive at the time of data collection. Conclusions Daptomycin MIC distribution for EBSI isolates suggests a high local rate of susceptibility, according to CLSI breakpoints, in a population with high rates of VREfm. CLSI-recommended doses of daptomycin were used, with encouraging survival outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|